CL2023001344A1 - Formulaciones, métodos, kits y formas de dosificación - Google Patents

Formulaciones, métodos, kits y formas de dosificación

Info

Publication number
CL2023001344A1
CL2023001344A1 CL2023001344A CL2023001344A CL2023001344A1 CL 2023001344 A1 CL2023001344 A1 CL 2023001344A1 CL 2023001344 A CL2023001344 A CL 2023001344A CL 2023001344 A CL2023001344 A CL 2023001344A CL 2023001344 A1 CL2023001344 A1 CL 2023001344A1
Authority
CL
Chile
Prior art keywords
formulations
kits
methods
dosage forms
amd3100
Prior art date
Application number
CL2023001344A
Other languages
English (en)
Inventor
Sun Zhaoli
Sun John
GRIFFIN Jared
Eatmon Christy
Labell Rachel
Liu Zhimin
Brewer Richard
Agyemang Isaac
Williams Mitchell
Original Assignee
Medregen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medregen Llc filed Critical Medregen Llc
Publication of CL2023001344A1 publication Critical patent/CL2023001344A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las modalidades de la descripción se refieren en general a formulaciones, métodos, kits y formas de dosificación para mejorar la estabilidad que comprenden al menos dos ingredientes activos, AMD3100, o movilizador de células madre similar, y Tacrolimus, o derivado o análogo de FK506, y uno o más excipientes. Las formulaciones se pueden administrar como una inyección subcutánea de dosis individual. Las formulaciones pueden ser útiles en el tratamiento de diversas enfermedades, trastornos o lesiones.
CL2023001344A 2020-11-10 2023-05-10 Formulaciones, métodos, kits y formas de dosificación CL2023001344A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063111895P 2020-11-10 2020-11-10

Publications (1)

Publication Number Publication Date
CL2023001344A1 true CL2023001344A1 (es) 2023-11-03

Family

ID=81455536

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001344A CL2023001344A1 (es) 2020-11-10 2023-05-10 Formulaciones, métodos, kits y formas de dosificación

Country Status (11)

Country Link
US (1) US20220142992A1 (es)
EP (1) EP4243793A1 (es)
JP (1) JP2023549788A (es)
KR (1) KR20230106657A (es)
CN (1) CN116710086A (es)
AU (1) AU2021377219A1 (es)
CA (1) CA3198248A1 (es)
CL (1) CL2023001344A1 (es)
IL (1) IL302773A (es)
MX (1) MX2023005398A (es)
WO (1) WO2022103798A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286118T1 (de) * 1998-03-13 2005-01-15 Osiris Therapeutics Inc Anwendungen für humane nicht autologe, mesenchymale stammzellen
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
PL3030232T3 (pl) * 2013-04-29 2022-11-07 Medregen, Llc Gojenie ran poprzez autologiczną mobilizację komórek macierzystych
AU2016293581B2 (en) * 2015-07-16 2022-09-01 Medregen, Llc Pharmaceutical compositions useful for the treatment of tissue injury
MA46466A (fr) * 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite

Also Published As

Publication number Publication date
CN116710086A (zh) 2023-09-05
AU2021377219A1 (en) 2023-06-29
CA3198248A1 (en) 2022-05-19
US20220142992A1 (en) 2022-05-12
WO2022103798A1 (en) 2022-05-19
JP2023549788A (ja) 2023-11-29
MX2023005398A (es) 2023-06-28
IL302773A (en) 2023-07-01
KR20230106657A (ko) 2023-07-13
EP4243793A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
BRPI0608152A2 (pt) formulações para tratamento ocular
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2017016217A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
MX2021014634A (es) Formulaciones farmaceuticas antibacteriales de amplio espectro que comprenden lisozima y metodos de utilizar las mismas.
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
CL2023001344A1 (es) Formulaciones, métodos, kits y formas de dosificación
BR112023000287A2 (pt) 5-amino-2,3-dihidro-1,4-ftalazinadiona, combinação farmacêutica, composição farmacêutica, e, método de tratamento
DOP2023000171A (es) Formas de dosificación farmacéuticas que comprenden (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluorometil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
CO2023005726A2 (es) Formulación sólida
CN104524469A (zh) 一种跌打药酒
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
Jebelli et al. Effect of the Ethanolic Extract of Olibanum on the Expression of CaMKIIα Gene in B65 and PC12 Cells
CO2024002715A2 (es) Formulaciones de radiprodil
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
WO2020053712A3 (en) Agent for the treatment of skin wounds or burns